|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100047549 |
|
最近更新日期: Date of Last Refreshed on: |
2022-01-14 20:44:18 |
|
注册时间: Date of Registration: |
2021-06-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请与我们联系上传伦理批件。 ICU静脉血栓栓塞症(VTE)防控的持续质量改进的研究 |
|
Public title: |
Study in continuous quality improvement of prevention and control of venous thromboembolism (VTE) in ICU |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
浙江省ICU静脉血栓栓塞症(VTE)防控的持续质量改进:一项多中心、前瞻性、随机对照研究 |
|
Scientific title: |
Continuous quality improvement of prevention and control of venous thromboembolism (VTE) in ICU of Zhejiang Province: a multicenter, prospective, randomized controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
甄军海 |
研究负责人: |
甄军海 |
|
Applicant: |
Zhen Junhai |
Study leader: |
Zhen Junhai |
|
申请注册联系人电话: Applicant telephone: |
+86 15990079835 |
研究负责人电话: Study leader's telephone: |
+86 15990079835 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
15990079835@163.com |
研究负责人电子邮件: Study leader's E-mail: |
15990079835@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市西湖区灵隐路12号 |
研究负责人通讯地址: |
浙江省杭州市西湖区灵隐路12号 |
|
Applicant address: |
12 Lingyin Road, Xihu District, Hangzhou, Zhejiang |
Study leader's address: |
12 Lingyin Road, Xihu District, Hangzhou, Zhejiang |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江医院 |
||
|
Applicant's institution: |
Zhejiang Hospital |
||
|
研究负责人所在单位: |
浙江医院 |
||
|
Affiliation of the Leader: |
Zhejiang Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020临审第(98K)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
浙江医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of Zhejiang Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
何晓波 |
||
|
Contact Name of the ethic committee: |
He Xiaobo |
||
|
伦理委员会联系地址: |
浙江省杭州市西湖区灵隐路12号 |
||
|
Contact Address of the ethic committee: |
12 Lingyin Road, Xihu District, Hangzhou, Zhejiang |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
浙江医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhejiang Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市西湖区灵隐路12号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
12 Lingyin Road, Xihu District, Hangzhou, Zhejiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2021年浙江省医药卫生科技计划项目(2021450592) |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhejiang Provincial Programme for the Zhejiang Medical and Health Science and Technology Programme in 2021 (2021450592) |
||||||||||||||||||||||
|
Target disease: |
venous thromboembolism (VTE) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过本课题研究,深入探讨持续质量改进对浙江省ICU VTE防控水平的影响,为以后开展VTE持续质量改进提供更加科学的客观依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Through this study, the effect of continuous quality improvement on the prevention and control level of VTE in ICU of Zhejiang Province is deeply discussed, which will provide more scientific and objective basis for future continuous quality improvement of VTE. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄大于18岁的ICU患者; |
||||||||||||||||||||||
|
Inclusion criteria |
1.ICU patients over 18 years old; |
||||||||||||||||||||||
|
排除标准: |
1.入住ICU前已经被确诊为DVT或肺栓塞; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.DVT or pulmonary embolism had been diagnosed before admission to ICU; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-01-01 00:00:00至 To 2023-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2022-01-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
计算机产生随机序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Computer generated random sequence. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
伊柯夫临床试验管理平台,http://ecrf88.3qtrials.com:8017。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Ikov clinical trial management platform, http://ecrf88.3qtrials.com:8017. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表+电子采集和管理系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form + Electronic acquisition and management system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |